SCHEMBL30440404

CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)C(N)=O

nearest known ligand 0.60

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	C5AR1	P21730	1/20	0.60

▸	GLP1R	P43220	3/20	0.59

▸	GCGR	P47871	3/20	0.59

▸	NPBWR1	P48145	12/20	0.58

▸	NMBR	P28336	2/20	0.58

▸	GRPR	P30550	2/20	0.58

▸	CXCR4	P61073	2/20	0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30439719	0.96	C5AR1 (0.62)	C5AR1GLP1RGCGRNPBWR1NMBR
SCHEMBL30440054	0.94	C5AR1 (0.64)	C5AR1GLP1RGCGRNPBWR1NMBR
SCHEMBL30439604	0.94	C5AR1 (0.64)	C5AR1GLP1RGCGRNPBWR1NMBR
SCHEMBL30439693	0.93	C5AR1 (0.65)	C5AR1GLP1RGCGRNPBWR1NMBR
SCHEMBL30439192	0.93	C5AR1 (0.63)	C5AR1GLP1RGCGRNPBWR1NMBR
SCHEMBL30439962	0.93	C5AR1 (0.61)	C5AR1GLP1RGCGRNPBWR1NMBR
SCHEMBL30439794	0.92	C5AR1 (0.60)	C5AR1GLP1RGCGRNMBRGRPR
SCHEMBL30440226	0.92	CTSL (0.62)	C5AR1GLP1RGCGRNMBRGRPR
SCHEMBL30439707	0.92	CTSL (0.62)	C5AR1GLP1RGCGRNMBRGRPR
SCHEMBL30439232	0.92	CTSL (0.62)	C5AR1GLP1RGCGRNMBRGRPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230173086-A1	PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES	EAGLE RESOLUTE INVESTMENT LLC	2023-06-08	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230173086-A1	PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES	VIP, DNPEP, CD74	C5AR1 140/4885GLP1R 501/4885GCGR 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.